Disruption of gut barrier integrity and host–microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus

References

• Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, Wai‐Sun Wong V, Yilmaz Y, George J, Fan J, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatol. 2019;69(6):2672–16. doi:10.1002/hep.30251.
   PubMed Web of Science ®Google Scholar
• Younossi Z, Stepanova M, Ong JP, Jacobson IM, Bugianesi E, Duseja A, Eguchi Y, Wong VW, Negro F, Yilmaz Y, et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2019;17(4):748–755.e3. doi:10.1016/j.cgh.2018.05.057. published Online First: 2018/06/17.
   PubMed Web of Science ®Google Scholar
• Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatol. 2018;67(1):123–133. doi:10.1002/hep.29466. published Online First: 2017/12/01.
   PubMed Web of Science ®Google Scholar
• Ekta Gupta E, Gupta M, Kaur A, Singh TG, Bedi O. Pathobiological and molecular connections involved in the high fructose and high fat diet induced diabetes associated nonalcoholic fatty liver disease. Inflamm Res. 2020;69(9):851–867. doi:10.1007/s00011-020-01373-7. published Online First: 2020/06/23.
   PubMed Web of Science ®Google Scholar
• Bedi O, Aggarwal S, Trehanpati N, Ramakrishna G, Krishan P. Molecular and pathological events involved in the pathogenesis of diabetes-associated nonalcoholic fatty liver disease. J Clin Exp Hepatol. 2019;9(5):607–618. doi:10.1016/j.jceh.2018.10.004. published Online First: 2018/11/12.
   PubMed Web of Science ®Google Scholar
• Bedi O, Srivastava N, Parsad D, Krishan P. Fatty acid synthase inhibition ameliorates diabetes induced liver injury in rodent experimental model. Eur J Pharmacol. 2021;901:174078. doi:10.1016/j.ejphar.2021.174078. published Online First: 2021/04/09.
   PubMed Web of Science ®Google Scholar
• Aron-Wisnewsky J, Vigliotti C, Witjes J, Le P, Holleboom AG, Verheij J, Nieuwdorp M, Clément K. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol. 2020;17(5):279–297. doi:10.1038/s41575-020-0269-9. published Online First: 2020/03/09.
   PubMed Web of Science ®Google Scholar
• Qin Y, Havulinna AS, Liu Y, Jousilahti P, Ritchie SC, Tokolyi A, Sanders JG, Valsta L, Brożyńska M, Zhu Q, et al. Combined effects of host genetics and diet on human gut microbiota and incident disease in a single population cohort. Nat Genet. 2022;54(2):134–42. doi:10.1038/s41588-021-00991-z. published Online First: 2022/02/03.
   PubMed Web of Science ®Google Scholar
• Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy P, Grose R, Cummins A. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut. 2001;48(2):206–211. doi:10.1136/gut.48.2.206. published Online First: 2001/01/13.
   PubMed Web of Science ®Google Scholar
• Forlano R, Mullish BH, Roberts LA, Thursz MR, Manousou P. The intestinal barrier and its dysfunction in patients with metabolic diseases and non-alcoholic fatty liver disease. Int J Mol Sci. 2022;23(2):662. doi:10.3390/ijms23020662. published Online First: 2022/01/08.
   PubMed Web of Science ®Google Scholar
• Sartini A, Gitto S, Bianchini M, Verga MC, Di Girolamo M, Bertani A, Del Buono M, Schepis F, Lei B, De Maria N, et al. Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease. Cell Death Disease. 2018;9(2):87. doi:10.1038/s41419-017-0124-2. published Online First: 2018/01/24.
   PubMedGoogle Scholar
• Luci C, Bourinet M, Leclere PS, Anty R, Gual P. Chronic inflammation in non-alcoholic steatohepatitis: molecular mechanisms and therapeutic strategies. Front Endocrinol (Lausanne). 2020;11:597648. doi:10.3389/fendo.2020.597648. published Online First: 2021/01/02.
   PubMed Web of Science ®Google Scholar
• Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, Dulai PS, Caussy C, Bettencourt R, Highlander SK, et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab. 2019;30(3):607. doi:10.1016/j.cmet.2019.08.002.
   PubMed Web of Science ®Google Scholar
• Oh TG, Kim SM, Caussy C, Fu T, Guo J, Bassirian S, Singh S, Madamba EV, Bettencourt R, Richards L, et al. A universal gut-microbiome-derived signature predicts cirrhosis. Cell Metab. 2020;32(5):878–888.e6. doi:10.1016/j.cmet.2020.06.005. published Online First: 2020/06/30.
   PubMed Web of Science ®Google Scholar
• Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JFWM, Dallinga–Thie GM, Ackermans MT, Serlie MJ, Oozeer R, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterol. 2012;143(4):913–916.e7. doi:10.1053/j.gastro.2012.06.031. published Online First: 2012/06/26.
   PubMed Web of Science ®Google Scholar
• Su L, Hong Z, Zhou T, Jian Y, Xu M, Zhang X, Zhu X, Wang J. Health improvements of type 2 diabetic patients through diet and diet plus fecal microbiota transplantation. Sci Rep. 2022;12(1):1152. doi:10.1038/s41598-022-05127-9. published Online First: 2022/01/21.
   PubMed Web of Science ®Google Scholar
• Raman M, Ahmed I, Gillevet PM, Probert CS, Ratcliffe NM, Smith S, Greenwood R, Sikaroodi M, Lam V, Crotty P, et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2013;11(7):868–875.e3. doi:10.1016/j.cgh.2013.02.015. published Online First: 2013/03/05.
   PubMed Web of Science ®Google Scholar
• Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fung SK, Fischer SE, McGilvray ID, Allard JP. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatol. 2013;58(1):120–127. doi:10.1002/hep.26319. published Online First: 2013/02/13.
   PubMed Web of Science ®Google Scholar
• Forlano R, Jayawardana S, Mullish B, Yee M, Mossialos E, Goldin R, Petta S, Tsochatzis E, Thursz M, Manousou P. Clinical and cost-effectiveness analysis of community-based screening strategies for non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. 2020. doi:10.21203/rs.3.rs-2135338/v1.
   Google Scholar
• Hoyles L, Fernandez-Real JM, Federici M, Serino M, Abbott J, Charpentier J, Heymes C, Luque JL, Anthony E, Barton RH, et al. Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. Nat Med. 2018;24(7):1070–80. doi:10.1038/s41591-018-0061-3. published Online First: 2018/06/25.
   PubMed Web of Science ®Google Scholar
• Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stål P, Kechagias S, Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatol. 2015;61(5):1547–1554. doi:10.1002/hep.27368. published Online First: 2015/03/23.
   PubMed Web of Science ®Google Scholar
• Lanthier N, Rodriguez J, Nachit M, Hiel S, Trefois P, Neyrinck AM, Cani PD, Bindels LB, Thissen JP, Delzenne NM, et al. Microbiota analysis and transient elastography reveal new extra-hepatic components of liver steatosis and fibrosis in obese patients. Sci Rep. 2021;11(1):659. doi:10.1038/s41598-020-79718-9. published Online First: 2021/01/12.
   PubMed Web of Science ®Google Scholar
• Diviccaro S, Falvo E, Piazza R, Cioffi L, Herian M, Brivio P, Calabrese F, Giatti S, Caruso D, Melcangi RC, et al. Gut microbiota composition is altered in a preclinical model of type 1 diabetes mellitus: influence on gut steroids, permeability, and cognitive abilities. Neuropharmacol. 2023;226:109405. doi:10.1016/j.neuropharm.2022.109405. published Online First: 2022/12/23.
   PubMed Web of Science ®Google Scholar
• Forlano R, Mullish BH, Dhar A, Goldin RD, Thursz M, Manousou P. Liver function tests and metabolic-associated fatty liver disease: changes in upper normal limits, does it really matter? World J Hepatol. 2021;13(12):2104–2112. doi:10.4254/wjh.v13.i12.2104. published Online First: 2022/01/25.
   PubMed Web of Science ®Google Scholar
• Berzigotti A, Tsochatzis E, Boursier J, Castera L, Cazzagon N, Friedrich-Rust M, Petta S, Thiele M, European Association for the Study of the Liver, Electronic address eee, Clinical Practice Guideline P, Chair. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. J Hepatol. 2021;75(3):659–689. doi:10.1016/j.jhep.2021.05.025. published Online First: 2021/06/21.
   PubMed Web of Science ®Google Scholar
• Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J, et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci U S A. 2001;98(6):3369–74. doi:10.1073/pnas.051551698.
   PubMed Web of Science ®Google Scholar
• Mouzaki M, Wang AY, Bandsma R, Comelli EM, Arendt BM, Zhang L, Fung S, Fischer SE, McGilvray IG, Allard JP, et al. Bile acids and dysbiosis in non-alcoholic fatty liver disease. PloS ONE. 2016;11(5):e0151829. doi:10.1371/journal.pone.0151829. published Online First: 2016/05/20.
   PubMed Web of Science ®Google Scholar
• Cynober L. Metabolism of dietary glutamate in adults. Ann Nutr Metab. 2018;73(Suppl 5):5–14. doi:10.1159/000494776. published Online First: 2018/12/07.
   PubMedGoogle Scholar
• Du K, Chitneni SK, Suzuki A, Wang Y, Henao R, Hyun J, Premont RT, Naggie S, Moylan CA, Bashir MR, et al. Increased glutaminolysis marks active scarring in nonalcoholic steatohepatitis progression. Cell Mol Gastroenterol Hepatol. 2020;10(1):1–21. doi:10.1016/j.jcmgh.2019.12.006. published Online First: 2019/12/28.
   PubMed Web of Science ®Google Scholar
• Ortiz C, Schierwagen R, Schaefer L, Klein S, Trepat X, Trebicka J. Extracellular matrix remodeling in chronic liver disease. Curr Tissue Microenviron Rep. 2021;2(3):41–52. doi:10.1007/s43152-021-00030-3. published Online First: 2021/07/23.
   PubMedGoogle Scholar
• Kagan HM, Li W. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem. 2003;88(4):660–72. doi:10.1002/jcb.10413.
   PubMed Web of Science ®Google Scholar
• Yoshida N, Emoto T, Yamashita T, Watanabe H, Hayashi T, Tabata T, Hoshi N, Hatano N, Ozawa G, Sasaki N, et al. Bacteroides vulgatus and bacteroides dorei reduce gut microbial lipopolysaccharide production and inhibit atherosclerosis. Circulat. 2018;138(22):2486–98. doi:10.1161/CIRCULATIONAHA.118.033714. published Online First: 2018/12/21.
   PubMed Web of Science ®Google Scholar
• De Munck TJI, Xu P, Verwijs HJA, Masclee AAM, Jonkers D, Verbeek J, Koek GH. Intestinal permeability in human nonalcoholic fatty liver disease: a systematic review and meta-analysis. Liver Int. 2020;40(12):2906–2916. doi:10.1111/liv.14696. published Online First: 2020/10/11.
   PubMed Web of Science ®Google Scholar
• Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, Mascianà R, Forgione A, Gabrieli ML, Perotti G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatol. 2009;49(6):1877–87. doi:10.1002/hep.22848. published Online First: 2009/03/18.
   PubMed Web of Science ®Google Scholar
• Machado MV, Yang Y, Diehl AM. The benefits of restraint: a pivotal role for IL-13 in hepatic glucose homeostasis. J Clin Invest. 2013;123(1):115–7. doi:10.1172/JCI67238. published Online First: 2012/12/21.
   PubMed Web of Science ®Google Scholar
• Kim BK, Tamaki N, Imajo K, Yoneda M, Sutter N, Jung J, Lin T, Tu XM, Bergstrom J, Nguyen K, et al. Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD. J Hepatol. 2022;77(6):1482–90. doi:10.1016/j.jhep.2022.07.020. published Online First: 2022/08/13.
   PubMed Web of Science ®Google Scholar
• Anstee QM, Hallsworth K, Lynch N, Hauvespre A, Mansour E, Kozma S, Marino J-P, Bottomley J, Piercy J, Higgins V, et al. Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions. JHEP Reports. 2022;4(1):100411. doi:10.1016/j.jhepr.2021.100411. published Online First: 2021/11/22.
   PubMedGoogle Scholar
• Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, Clark JM. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatol. 2011;54(3):1082–1090. doi:10.1002/hep.24452.
   PubMed Web of Science ®Google Scholar
• Sarafian MH, Lewis MR, Pechlivanis A, Ralphs S, McPhail MJW, Patel VC, Dumas M-E, Holmes E, Nicholson JK. Bile acid profiling and quantification in biofluids using ultra-performance liquid chromatography tandem mass spectrometry. Anal Chem. 2015;87(19):9662–9670. doi:10.1021/acs.analchem.5b01556. published Online First: 2015/09/04.
   PubMed Web of Science ®Google Scholar
• Gratton J, Phetcharaburanin J, Mullish BH, Williams HRT, Thursz M, Nicholson JK, Holmes E, Marchesi JR, Li JV. Optimized sample handling strategy for metabolic profiling of human feces. Anal Chem. 2016;88(9):4661–4668. doi:10.1021/acs.analchem.5b04159. published Online First: 2016/04/21.
   PubMed Web of Science ®Google Scholar
• Mullish BH, Pechlivanis A, Barker GF, Thursz MR, Marchesi JR, McDonald JAK. Functional microbiomics: evaluation of gut microbiota-bile acid metabolism interactions in health and disease. Methods. 2018;149:49–58. doi:10.1016/j.ymeth.2018.04.028. published Online First: 2018/04/29.
   PubMed Web of Science ®Google Scholar
• Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. Appl Environ Microbiol. 2013;79(17):5112–5120. doi:10.1128/AEM.01043-13. published Online First: 2013/06/25.
   PubMed Web of Science ®Google Scholar
• Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. DADA2: High-resolution sample inference from Illumina amplicon data. Nat Methods. 2016;13(7):581–583. doi:10.1038/nmeth.3869. published Online First: 2016/05/23.
   PubMed Web of Science ®Google Scholar
• Whiley L, Nye LC, Grant I, Andreas N, Chappell KE, Sarafian MH, Misra R, Plumb RS, Lewis MR, Nicholson JK, et al. Ultrahigh-performance liquid chromatography tandem mass spectrometry with electrospray ionization quantification of tryptophan metabolites and markers of gut health in serum and plasma—application to clinical and epidemiology cohorts. Anal Chem. 2019;91(8):5207–5216. doi:10.1021/acs.analchem.8b05884. published Online First: 2019/03/25.
   PubMed Web of Science ®Google Scholar
• Dona AC, Jimenez B, Schafer H, Humpfer E, Spraul M, Lewis MR, Pearce JTM, Holmes E, Lindon JC, Nicholson JK, et al. Precision high-throughput proton NMR spectroscopy of human urine, serum, and plasma for large-scale metabolic phenotyping. Anal Chem. 2014;86(19):9887–94. doi:10.1021/ac5025039. published Online First: 2014/09/03.
   PubMed Web of Science ®Google Scholar
• Beckonert O, Keun HC, Ebbels TM, Bundy J, Holmes E, Lindon JC, Nicholson JK. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc. 2007;2(11):2692–2703. doi:10.1038/nprot.2007.376. published Online First: 2007/11/17.
   PubMed Web of Science ®Google Scholar
• Takis PG, Jimenez B, Sands CJ, Chekmeneva E, Lewis MR. SMolESY: an efficient and quantitative alternative to on-instrument macromolecular1H-NMR signal suppression. Chem Sci. 2020;11(23):6000–6011. doi:10.1039/d0sc01421d. published Online First: 2021/06/08.
   PubMed Web of Science ®Google Scholar
• Takis PG, Jimenez B, Al-Saffar NMS, Harvey N, Chekmeneva E, Misra S, Lewis MR. A computationally lightweight algorithm for deriving reliable metabolite panel measurements from 1D 1H NMR. Anal Chem. 2021;93(12):4995–5000. doi:10.1021/acs.analchem.1c00113. published Online First: 2021/03/18.
   PubMed Web of Science ®Google Scholar
• Jimenez B, Holmes E, Heude C, Tolson RF, Harvey N, Lodge SL, Chetwynd AJ, Cannet C, Fang F, Pearce JTM, et al. Quantitative lipoprotein subclass and low molecular weight metabolite analysis in human serum and plasma by 1H NMR spectroscopy in a multilaboratory trial. Anal Chem. 2018;90(20):11962–11971. doi:10.1021/acs.analchem.8b02412. published Online First: 2018/09/27.
   PubMed Web of Science ®Google Scholar
• Martinez-Gili L, McDonald JAK, Liu Z, Kao D, Allegretti JR, Monaghan TM, Barker GF, Miguéns Blanco J, Williams HRT, Holmes E, et al. Understanding the mechanisms of efficacy of fecal microbiota transplant in treating recurrent clostridioides difficile infection and beyond: the contribution of gut microbial-derived metabolites. Gut Microbes. 2020;12(1):1810531. doi:10.1080/19490976.2020.1810531.
   PubMed Web of Science ®Google Scholar
• McMurdie PJ, Holmes S, Watson M. Phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PloS ONE. 2013;8(4):e61217. doi:10.1371/journal.pone.0061217. published Online First: 2013/04/22.
   PubMed Web of Science ®Google Scholar
• Gloor GB, Macklaim JM, Pawlowsky-Glahn V, Egozcue JJ. Microbiome datasets are compositional: and this is not optional. Front Microbiol. 2017;8:2224. doi:10.3389/fmicb.2017.02224. published Online First: 2017/11/15.
   PubMed Web of Science ®Google Scholar
• Thevenot EA, Roux A, Xu Y, Ezan E, Junot C. Analysis of the human adult urinary metabolome variations with age, body mass index, and gender by implementing a comprehensive workflow for univariate and OPLS statistical analyses. J Proteome Res. 2015;14(8):3322–3335. doi:10.1021/acs.jproteome.5b00354. published Online First: 2015/07/02.
   PubMed Web of Science ®Google Scholar
• Lin H, Peddada SD. Analysis of compositions of microbiomes with bias correction. Nat Commun. 2020;11(1):3514. doi:10.1038/s41467-020-17041-7. published Online First: 2020/07/14.
   PubMed Web of Science ®Google Scholar
• Martinez-Gili L, Pechlivanis A, McDonald JAK, Begum S, Badrock J, Dyson JK, Jones R, Hirschfield G, Ryder SD, Sandford R, et al. Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis. Gut Microbes. 2023;15(1):2208501. doi:10.1080/19490976.2023.2208501.
   PubMed Web of Science ®Google Scholar